GBSN

gbscience.com/investor-presentation/
Investor Presentation

posted on July 7, 2017 in Featured, Investors
GBSN Investor Deck – July 2017_FINAL

gbscience.com/wp-content/uploads/...eck-July-2017_FINAL-1.pptx

Habe an GBSN geschrieben, ob es die Präsentation nicht besser als PDF-Datei geben sollte, wie es ja auch auf dem Button steht, statt als PPTX-Datei.

Scott Gordon von GBSN hat geantwortet: "Better if it is a pdf. For sure."

Hier der PDF-Link für die heutige Präsentation:
gbscience.com/wp-content/uploads/...r-Deck-July-2017_FINAL.pdf

Ist jetzt auch so auf der Website aufrufbar.

Capital Structure

▪ Common shares & equivalents outstanding–11.6MM (incl. shares from Series K Warrants)
▪ No variable priced instruments
▪ $20.3 million Series A Convertible Note
▪ Convertible at $3.00 a share, no resets or variable rate conversions, 6.8 million shares
▪ Not convertible for 6 months from issuance (April 17, 2017)
▪ Other debt of $1.8MM, including $0.1MM Series B Convertible Note, convertible at $1.10
▪ Enterprise value of approximately $26.7MM
▪ Series J warrants are exercisable into 22.4MM shares until August 21, 2017
▪ Exercise price of $0.30 (subject to adjustment by the Company)
 

haben sich seit der Veröffentlichung der Präsentation am Freitag etwas verbessert.

Artikel:

www.finanznachrichten.de/...gangenheit-gesunde-zukunft-620.htm
 

Great Basin Scientific Receives FDA 510(k) Clearance for Stool Bacterial Pathogens Panel

globenewswire.com/news-release/2017/07/13/...hogens-Panel.html
 

"...These evaluations alone represent the potential for nearly $2.0 million in annual revenue for the Company, which historically has had an 82% win rate for its product evaluations. With this FDA clearance, the Company will begin to actively market SBPP to its current customer base of over 230 hospitals and labs, and will commence aggressive outreach to potential new customers. Sites that have evaluated and are ready to adopt the panel can now purchase kits to report patient results. ..."

"...As announced in the Company’s Business Update on June 26, 2017, the Company had approximately $5.0 million of potential new revenues in the new business pipeline, of which SBPP comprises nearly $2.0 million. These potential revenue estimates, as well as those below are based on the evaluating site’s own estimate of their expected testing volumes multiplied by the product price offered to the prospective customer. ..."

und die Amis sind ganz wild auf GBSN. Aber die Warrants bremsen natürlich gewaltig.

schlecht aus.

Hab mich dazu hinreissen lassen, noch ein paar GBSN zu kaufen. Wird schon schiefgehen.

Nun alles bereinigt?

......

Weiterlesen im Thread

http://www.ariva.de/forum/...kaufkurse-547917?new_pnr=23017013#bottom

Beitrag #6

Hab mich schon gewundert, daß hier außer mir keiner gepostet hat. Hab hier aus alter Gewohnheit weitergeschrieben, ohne den neuen Thread zu bemerken.

http://www.ariva.de/forum/...auf-nun-kaufkurse-547917?page=0#jumppos5